Ohashi et al reported that alogliptin improved steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels, in 11 patients with chronic kidney disease. The gene discussed is GLP1R; the disease is chronic kidney disease.